Back

The impact of statins and RAS inhibitors on the association between delayed antidiabetic treatment and the risk of cardiovascular event in patients with a first HbA1c between 48-57 mmol/mol

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Diabetes and the heart 2 Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Alexander Christian Falkentoft

Zealand University Hospital, Roskilde (Denmark)

7 More presentations in this session

Presentation thumbnail
Microvascular complications, coronary artery disease and the risk of cardiovascular disease in diabetes patients undergoing coronary angiography: a cohort study from the Western Denmark Heart Registry
Doctor K. Olesen (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Residual inflammatory risk appeared related to weight, atherogenic lipid profile and biomarkers of inflammation, but not to glycaemic control in type 1 diabetes
Doctor N. J Johansen (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Cumulative hyperinsulinemia, hyperglycaemia, and insulin resistance from mid-adolescence through young adulthood with carotid intima-media thickness progression: A 9-year longitudinal study
Associate Professor J. Zachariah (Houston, US)
Abstract Slides
Presentation thumbnail
The exercise tolerance dependence on epicardial fat thickness, right ventricular hypertrophy and right ventricular global function in patients with metabolic syndrome
Assistant Professor E. Argint (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Influence of long-term sodium-glucose cotransporter 2 inhibition on cardiac remodeling in rats with type 1 diabetes mellitus
Mr E. Rodrigues (Botucatu, BR)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and the heart 2

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources